Jul 24, 2014, 00:00
by
Michael Croft
PRINCETON, NJ - Jul 24, 2014 - WIRB-Copernicus Group (“WCG”), the world’s largest provider of regulatory and ethical review services for clinical research, announced today that it has acquired Alliance Biosciences
Expanding bio-risk management support for
federal, state and institutional laboratories
PRINCETON, NJ - Jul 24, 2014 - WIRB-Copernicus Group (WCG),
the worlds largest provider of regulatory and ethical review
services for clinical research, announced today that it has
acquired Alliance Biosciences. Formerly a division of Richmond,
VA-based Alliance Engineering, Alliance Biosciences was the leading
biosafety and biosecurity consulting firm in the United States.
With this addition, WCGs biosafety division - WCG Biosafety -
will be able to manage the entire continuum of biosafety oversight,
helping to ensure that research involving potentially hazardous
agents and vectors complies with the appropriate safety and
regulatory requirements from laboratory design and drug discovery
through clinical testing and therapeutic application.
Recent news headlines regarding the mishandling of smallpox
virus, avian influenza virus, and anthrax bacteria by government
healthcare agencies underscore the importance of biosafety
oversight for the public as well as industry professionals, said
WCG Chairman & Chief Executive Officer Donald A. Deieso, Ph.D.
With this expansion to our WCG Biosafety team, we can now oversee
all aspects of the biosafety review process from building the
laboratories and organizing materials to managing the regulatory
review boards and ethical approval process for drugs in
development.
My colleagues and I are tremendously proud to join WCG, and to
expand our service offering to create a unified, seamless biosafety
solution, said Ryan Burnette, Ph.D., former director of Alliance
Biosciences and newly-appointed vice president of WCG Biosafety.
Biological science is a driving force in our society. As the
promise of gene therapy increases, vaccine development expands, and
the industry continues to explore new applications for infectious
agents, the need for biosafety and biosecurity is more important
than ever. We can make a greater impact as part of an organization
that has for its mission the advancement of science and the
protection of life.
The most experienced provider of biosafety solutions, WCG
Biosafety manages more than 200 Institutional Biosafety Committees
(IBCs) and has evaluated more than 140 gene transfer clinical and
recombinant DNA pre-clinical research protocols to date. That is
more reviews than any other U.S. organization outside of the Food
and Drug Administration and the National Institutes of Health. IBCs
are considered the cornerstone of the oversight process for any
research involving recombinant and synthetic nucleic acid - gene
therapies - at the institutions where the studies are being
conducted.
WCG Biosafety brings together the leading authorities in
biosafety, biosecurity, and bio-risk management to provide
comprehensive review services and consulting solutions to
government organizations, pharma and biotech companies, private
research organizations, and academic institutions around the
world.
WCG Biosafety helps these organizations to ensure the protection
of human subjects, the safety of their investigators and personnel,
and the security of their laboratories and workspaces. In addition
to providing administrative support and mentoring for IBCs and
biosafety officers, WCG Biosafety also specializes in containment
laboratory design (BSL-1/2/3/4) guidance, facility evaluations,
documentation and program audits, risk/threat assessments, and
custom biosafety training.
Jenna Hess, M.S., who was formerly deputy director at Alliance
Biosciences, has also joined WCG Biosafety as the divisions
director of operations.
About the WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is the world's largest provider of
regulatory and ethical solutions for clinical research, including
Institutional Review Board (IRB) and Institutional Biosafety
Committee (IBC) review. The pioneer of independent ethical
oversight, WCG continues to drive progress in the clinical research
space. Today, WCGs solutions are built upon the foundation of
ethical review, but have grown to include a suite of complementary
services and technologies. These offerings include electronic
informed-consent solutions, interactive Part 11-compliant online
learning management solutions for clinical research professionals,
and software compliance and research oversight solutions for
institutions. WCG leverages its industry insight to stimulate
growth, foster compliance, and maximize efficiency for those who
perform clinical trials.
For more information, please visit www.wcgclinical.com or
follow us on Twitter @WCGClinical.